Ignite Creation Date:
2024-05-05 @ 4:37 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00281892
Status:
COMPLETED
Last Update Posted:
2018-05-11
First Post:
2006-01-24
Brief Title:
Fludarabine and Darbepoetin Alfa in Treating Older Patients With Chronic Lymphocytic Leukemia
Sponsor:
German CLL Study Group
Organization:
German CLL Study Group
Study Overview
Official Title:
Darbepoetin Alfa in Patients With Chronic Lymphocytic Leukemia and Comorbidity
Status:
COMPLETED
Status Verified Date:
2018-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Drugs used in chemotherapy such as fludarabine work in different ways to stop the growth of cancer cells either by killing the cells or by stopping them from dividing Darbepoetin alfa may cause the body to make more red blood cells It is not yet known whether fludarabine is more effective with or without darbepoetin alfa in treating chronic lymphocytic leukemia
PURPOSE This phase III trial is studying fludarabine to see how well it works when given together with or without darbepoetin alfa in treating older patients with chronic lymphocytic leukemia
PURPOSE This phase III trial is studying fludarabine to see how well it works when given together with or without darbepoetin alfa in treating older patients with chronic lymphocytic leukemia
Detailed Description:
OBJECTIVES
Compare the efficacy of fludarabine with or without darbepoetin alfa in geriatric patients with chronic lymphocytic leukemia and relevant comorbidities
Determine the effect of these regimens in reducing anemia lowering the requirements of transfusion and reducing the duration and frequency of hospitalization in these patients
Determine the quality of life of patients treated with these regimens
Determine event-free progression-free and overall survival of patients treated with these regimens
Evaluate the medical-economical aspects of these regimens in these patients
OUTLINE This is a multicenter study Patients are stratified according to hemoglobin value 12 gdL stratum 1 vs 12 gdL stratum 2 Patients are assigned to 1 of 2 treatment strata
Stratum 1 Patients receive fludarabine IV on days 1 3 and 5 Treatment repeats every 28 days for up to 6 courses Patients also receive darbepoetin alfa subcutaneously once weekly for up to 6 weeks
Stratum 2 Patients receive fludarabine as in stratum 1 Quality of life is evaluated periodically
PROJECTED ACCRUAL A total of 348 patients will be accrued for this study
Compare the efficacy of fludarabine with or without darbepoetin alfa in geriatric patients with chronic lymphocytic leukemia and relevant comorbidities
Determine the effect of these regimens in reducing anemia lowering the requirements of transfusion and reducing the duration and frequency of hospitalization in these patients
Determine the quality of life of patients treated with these regimens
Determine event-free progression-free and overall survival of patients treated with these regimens
Evaluate the medical-economical aspects of these regimens in these patients
OUTLINE This is a multicenter study Patients are stratified according to hemoglobin value 12 gdL stratum 1 vs 12 gdL stratum 2 Patients are assigned to 1 of 2 treatment strata
Stratum 1 Patients receive fludarabine IV on days 1 3 and 5 Treatment repeats every 28 days for up to 6 courses Patients also receive darbepoetin alfa subcutaneously once weekly for up to 6 weeks
Stratum 2 Patients receive fludarabine as in stratum 1 Quality of life is evaluated periodically
PROJECTED ACCRUAL A total of 348 patients will be accrued for this study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2005-003014-15 | EUDRACT_NUMBER | None | None |
| GCLLSG-CLL9 | None | None | None |
| EU-20561 | None | None | None |
| AMGEN-GCLLSG-CLL9 | None | None | None |